Confident Investing Starts With TipRanks Premium

Get 55% Off
TipRanks
Go Ultimate55% OFF

Jazz Pharmaceuticals (J7Z) Stock Price & Analysis

J7Z Stock Chart & Stats

€190.75€5.10(2.75%)
At close: 5:30 PM GMT+1
EUR 190EUR 200EUR 210EUR 2203 Aug17 Aug1 Sep14 Sep24 Sep12 Oct29 Oct
Day’s Range
EUR 186.85 - EUR 190.75
52-Week Range
EUR 111.10 - EUR 229.50
Previous Close
EUR 185.65
Volume
40
Average Volume (3M)
6
Market Cap
EUR 12.51B
Enterprise Value
EUR 18.93B
Total Cash (Recent Filing)
EUR 2.20B
Total Debt (Recent Filing)
EUR 4.41B
Price to Earnings (P/E)
14.2
Beta
0.44
Next Earnings
Nov 02, 2026 (Est.)
EPS Estimate
-3.62
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Revenue And Product Growth

Broad-based growth across neuroscience and oncology products supports a durable expansion in Jazz’s commercial base. Higher guidance, strong Xywav and Epidiolex demand, and rapid Zepzelca growth indicate that multiple products—not one isolated asset—are contributing to revenue momentum.

Cash Generation And Leverage

Strong operating cash flow and materially lower leverage improve Jazz’s ability to fund clinical development, business development, and debt obligations internally. The combination of substantial liquidity and improved balance-sheet resilience provides greater flexibility if product investment or market conditions change.

Oncology Franchise Expansion

The Ziihera approval expands Jazz’s addressable oncology opportunity and positions the product in first-line HER2-positive gastroesophageal cancer. Its combination-based approval and reported survival benefits can support broader adoption, strengthen the oncology franchise, and diversify growth beyond sleep medicines.

Bears Say

Uneven Profitability

Although current profitability has improved, repeated historical losses show that earnings power has not been consistently stable. This volatility can complicate planning, reduce confidence in recurring earnings quality, and leave results more sensitive to product mix, development spending, and one-time charges.

Generic And Competitive Oxybate Risk

The oxybate franchise remains strategically important, so generic entry and emerging orexin alternatives could pressure patient retention, pricing, or future growth. Even with limited generic uptake so far, the risk may become more material as competitors gain market experience and commercial reach.

Margin And Investment Pressure

Higher royalties on growing products are already weighing on gross margin, while increased selling, research, and development costs raise the investment required to sustain expansion. If revenue growth moderates, this cost structure could limit operating leverage and compress earnings.

Jazz Pharmaceuticals News

J7Z FAQ

What was Jazz Pharmaceuticals’s price range in the past 12 months?
Jazz Pharmaceuticals lowest stock price was €111.10 and its highest was €229.50 in the past 12 months.
What is Jazz Pharmaceuticals’s market cap?
Jazz Pharmaceuticals’s market cap is €12.51B.
When is Jazz Pharmaceuticals’s upcoming earnings report date?
Jazz Pharmaceuticals’s next earnings report is estimated for Nov 02, 2026 (not yet confirmed), which is today.
How were Jazz Pharmaceuticals’s earnings last quarter?
Jazz Pharmaceuticals released its earnings results on Aug 03, 2026. The company reported €5.113 earnings per share for the quarter, missing the consensus estimate of €5.529 by -€0.416.
Is Jazz Pharmaceuticals overvalued?
According to Wall Street analysts Jazz Pharmaceuticals’s price is currently Undervalued.
Does Jazz Pharmaceuticals pay dividends?
Jazz Pharmaceuticals does not currently pay dividends.
What is Jazz Pharmaceuticals’s EPS estimate?
Jazz Pharmaceuticals’s EPS estimate is -3.62.
How many shares outstanding does Jazz Pharmaceuticals have?
Jazz Pharmaceuticals has 64,914,570 shares outstanding.
What happened to Jazz Pharmaceuticals’s price movement after its last earnings report?
Jazz Pharmaceuticals reported an EPS of €5.113 in its last earnings report, missing expectations of €5.529. Following the earnings report the stock price went down -0.184%.
Which hedge fund is a major shareholder of Jazz Pharmaceuticals?
Hedge funds hold Jazz Pharmaceuticals shares: the largest hedge-fund position in Jazz Pharmaceuticals is 1,138,783,479 shares, and hedge funds decreased their holdings by 228.2K shares last quarter.
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology